As suggested by analyses of each study alone, among the participants who received any active pharmacological treatments the ‘A’ allele of rs2036527 was associated with lower smoking abstinence rates (during treatment OR=0.42 and end of treatment OR=0.55, Fig.2C); adjusting for age, sex, baseline CPD, menthol status, type of counseling sessions and type of pharmacological treatment did not alter the association between rs2036527 and smoking abstinence (during treatment OR=0.42 and end of treatment OR=0.55, Fig.2C). Rs2036527 was not associated with smoking abstinence at 6-month follow up. The number needed to treat (NTT) was 8.9 for the GG group during active treatment (active treatment had no benefit in the GA/AA group). At the end of treatment, NTT were 9.3 and 22.8 for the GG and the GA/AA group, respectively. No statistically significant association between rs2036527 and smoking abstinence was observed at any time-point in the placebo arm, including after adjustment for age, sex, baseline CPD, menthol status, and type of counseling sessions (Fig.1D&2C).
